LONDON BROKER RATINGS: HSBC raises GSK; RBC cuts Close Brothers
(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday : Read More
| Price | 2,017.00p on 06-07-2026 at 11:10:25 |
|---|---|
| Change | 2.00p 0.1% |
| Buy | 2,018.00p |
| Sell | 2,017.00p |
| Last Trade: | Buy 714.00 at 2,017.00p |
| Day's Volume: | 801,512 |
| Last Close: | 2,015.00p |
| Open: | 2,025.00p |
| ISIN: | GB00BN7SWP63 |
| Day's Range | 2,015.00p - 2,048.00p |
| 52wk Range: | 1,315.00p - 2,282.00p |
| Market Capitalisation: | £80.79b |
| VWAP: | 2,031.57156p |
| Shares in Issue: | 4.01b |
Glaxosmithkline (GSK) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 714 | 2,017.00p | Automatic Execution |
12:10:25 - 06-Jul-26 |
| Buy* | 276 | 2,017.00p | Automatic Execution |
12:10:25 - 06-Jul-26 |
| Buy* | 275 | 2,017.00p | Automatic Execution |
12:10:25 - 06-Jul-26 |
| Buy* | 203 | 2,017.00p | Automatic Execution |
12:10:25 - 06-Jul-26 |
| Buy* | 324 | 2,017.00p | Automatic Execution |
12:10:25 - 06-Jul-26 |
| Unknown* | 0 | 2,017.00p | SI Trade |
12:10:25 - 06-Jul-26 |
| Buy* | 960 | 2,016.00p | Automatic Execution |
12:10:12 - 06-Jul-26 |
| Buy* | 318 | 2,016.00p | Automatic Execution |
12:10:12 - 06-Jul-26 |
| Buy* | 828 | 2,016.00p | Automatic Execution |
12:10:12 - 06-Jul-26 |
| Buy* | 150 | 2,016.00p | Automatic Execution |
12:10:12 - 06-Jul-26 |
Glaxosmithkline (GSK) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 1st Jul 2026 3:00 pm | RNS | Total Voting Rights |
| 29th Jun 2026 3:00 pm | RNS | Transaction in Own Shares |
| 29th Jun 2026 3:00 pm | RNS | Holding(s) in Company |
| 26th Jun 2026 3:00 pm | RNS | Holding(s) in Company |
| 24th Jun 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 24th Jun 2026 2:52 pm | RNS | GSK announces tender offer to acquire Nuvalent |
| 23rd Jun 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 22nd Jun 2026 3:00 pm | RNS | Transaction in Own Shares |
| 17th Jun 2026 4:06 pm | RNS | cUTI oral antibiotic Tebipenem approved by US FDA |
| 15th Jun 2026 3:00 pm | RNS | Transaction in Own Shares |